Medtronic announces U.S. Launch of the MiniMed® 630G system with new user-friendly insulin pump design and SmartGuard(TM) technology

In a recent press release, Medtronic plc (NYSE:MDT), the global leader in medical technology, announced the U.S. commercial launch of its MiniMed 630G system with SmartGuard technology FDA approved for the treatment of people with diabetes mellitus sixteen years of age and older.

Advertisement

The MiniMed 630G features a new insulin pump hardware platform and new user-friendly design that combines personalized diabetes management with industry-leading clinical performance. The MiniMed 630G system is the newest member of the MiniMed family-the most prescribed integrated insulin delivery system brand in the world.

After interviewing more than 1,000 people with diabetes and testing user-experience, the enhanced features of the MiniMed 630G system were finalized to take into account what matters most to those with diabetes. This collaborative process with the patient community resulted in a new, user-friendly pump design that is waterproof,1 has remote bolus functionality, and features a high-definition, full-color screen that supports easy navigation and enables increased customization with more intuitive menus.

The MiniMed 630G system exclusively uses the CONTOUR®NEXT LINK 2.4 blood glucose meter from Ascensia Diabetes Care to provide blood glucose test results that have been shown to be highly accurate2. The meter automatically transmits blood glucose results to calculate boluses using the Bolus Wizard® calculator and to calibrate the CGM sensor, which helps prevent manual entry errors. It also allows patients to discreetly give themselves a bolus of insulin remotely from the meter, providing added convenience to help patients manage their diabetes effectively.

“This latest innovation demonstrates Medtronic’s vision to transform diabetes care to enable greater freedom and better health through a commitment to continually improving both outcomes and user experience,” said Alejandro Galindo, president of the Intensive Insulin Management business at Medtronic. Click here to continue>

Advertisement

Next Up in Digital Health

Advertisement

Comments are closed.